Esperion Therapeutics (ESPR) Competitors $1.17 +0.02 (+1.83%) Closing price 07/3/2025 03:42 PM EasternExtended Trading$1.16 -0.01 (-0.51%) As of 07/3/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. CMRX, CDMO, AVXL, SNDX, AVBP, QURE, IMNM, GYRE, XERS, and CRONShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Chimerix (CMRX), Avid Bioservices (CDMO), Anavex Life Sciences (AVXL), Syndax Pharmaceuticals (SNDX), ArriVent BioPharma (AVBP), uniQure (QURE), Immunome (IMNM), Gyre Therapeutics (GYRE), Xeris Biopharma (XERS), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Its Competitors Chimerix Avid Bioservices Anavex Life Sciences Syndax Pharmaceuticals ArriVent BioPharma uniQure Immunome Gyre Therapeutics Xeris Biopharma Cronos Group Esperion Therapeutics (NASDAQ:ESPR) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk. Which has more risk & volatility, ESPR or CMRX? Esperion Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Chimerix has a beta of -0.17, suggesting that its stock price is 117% less volatile than the S&P 500. Which has preferable valuation and earnings, ESPR or CMRX? Esperion Therapeutics has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$332.31M0.70-$51.74M-$0.80-1.46Chimerix$212K3,778.71-$82.10M-$0.99-8.63 Is ESPR or CMRX more profitable? Chimerix has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -59.03%. Esperion Therapeutics' return on equity of -0.91% beat Chimerix's return on equity.Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-59.03% -0.91% -29.47% Chimerix N/A -50.78%-44.94% Do institutionals & insiders believe in ESPR or CMRX? 47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 1.7% of Esperion Therapeutics shares are owned by insiders. Comparatively, 13.1% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer ESPR or CMRX? In the previous week, Esperion Therapeutics had 2 more articles in the media than Chimerix. MarketBeat recorded 2 mentions for Esperion Therapeutics and 0 mentions for Chimerix. Esperion Therapeutics' average media sentiment score of 0.55 beat Chimerix's score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Esperion Therapeutics Positive Chimerix Neutral Do analysts prefer ESPR or CMRX? Esperion Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 497.78%. Chimerix has a consensus price target of $8.53, indicating a potential downside of 0.08%. Given Esperion Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Esperion Therapeutics is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Chimerix 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryEsperion Therapeutics beats Chimerix on 13 of the 16 factors compared between the two stocks. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$232.09M$2.41B$5.49B$9.02BDividend YieldN/A1.77%5.38%4.10%P/E Ratio-1.468.9827.4720.28Price / Sales0.70669.86408.86121.46Price / Cash47.86157.0736.6357.47Price / Book-0.594.638.095.68Net Income-$51.74M$31.34M$3.17B$248.96M7 Day Performance17.85%3.25%2.81%3.30%1 Month Performance4.55%6.80%3.67%5.20%1 Year Performance-50.38%1.89%35.41%21.37% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics4.1524 of 5 stars$1.17+1.8%$7.00+497.8%-50.4%$232.09M$332.31M-1.46200CMRXChimerix0.7572 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.7281 of 5 stars$12.50+0.1%$12.25-2.0%+62.3%$799.18M$139.91M-5.23320High Trading VolumeAVXLAnavex Life Sciences3.6325 of 5 stars$9.30+2.3%$44.00+373.1%+160.2%$793.94MN/A-16.9140Positive NewsSNDXSyndax Pharmaceuticals2.8607 of 5 stars$9.19-3.1%$35.91+290.7%-53.8%$790.80M$23.68M-2.38110AVBPArriVent BioPharma1.7739 of 5 stars$22.80-9.6%$39.29+72.3%+13.6%$779.99MN/A-6.0540High Trading VolumeQUREuniQure2.0001 of 5 stars$13.95-1.8%$37.82+171.1%+270.5%$764.18M$27.12M-3.18500News CoverageIMNMImmunome2.5532 of 5 stars$8.74-0.1%$23.33+167.0%-28.1%$760.47M$9.04M-2.7540Positive NewsGYREGyre Therapeutics0.0832 of 5 stars$7.77-3.7%N/A-30.5%$728.52M$105.76M388.6940XERSXeris Biopharma3.9172 of 5 stars$4.64+2.9%$6.25+34.7%+128.6%$725.63M$222.55M-15.47290Positive NewsCRONCronos Group2.3339 of 5 stars$1.87+0.5%N/A-12.1%$721.23M$124.59M14.39450News Coverage Related Companies and Tools Related Companies Chimerix Competitors Avid Bioservices Competitors Anavex Life Sciences Competitors Syndax Pharmaceuticals Competitors ArriVent BioPharma Competitors uniQure Competitors Immunome Competitors Gyre Therapeutics Competitors Xeris Biopharma Competitors Cronos Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESPR Stock Alerts